Legend Biotech Corp., a Somerset-based biopharmaceutical company, has named a new CEO and chairwoman, it announced this week.
The company’s chief financial officer and interim CEO, Ying Huang, was named to the permanent CEO job. He will continue to serve as CFO until a successor is found. In addition, Ye “Sally” Wang was named chairwoman of the board of directors.
“The entire board is very pleased to have Ms. Wang as Legend Biotech’s chairwoman,” Philip Yau, chair of the Audit Committee, said in a prepared statement. “Sally’s extensive experience and expertise in strategic planning and operational management will be instrumental as she leads our board and supports Legend Biotech’s management team in continuing to develop therapies for patients in need.”
Both appointments were effective last Friday, and with the unanimous approval of the board.
“Since taking on the role of interim CEO in September, Dr. Huang has seamlessly led Legend Biotech during a challenging time,” Wang said in a statement. “Dr. Huang’s strong business acumen and biotechnology expertise make him uniquely suited to advance Legend Biotech’s mission, and the board of directors has great confidence that he will continue to advance the important work that Legend Biotech is undertaking.”
Legend Biotech is a clinical-stage company developing novel cell therapies for oncology and other health care fields.
